MetaCap

Viking Therapeutics Inc. (VKTX)

NASDAQ: VKTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

24.77-1.07 (-4.14%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

VKTX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$5.42
52-week range
23.82 – 43.10
Day range
24.67 – 26.50
Volume / Avg
3.65M / 5.31M
Beta
—

52-week range

$23.82$43.10

VKTX stock today

Shares of Viking Therapeutics (VKTX) finished lower on Nov 20 at $24.77, a drop of 4.14% or $1.07 per share, versus the S&P 500's 3.70% decline. Shares are 42.5% below their 52-week high of $43.10, set on Sep 23, 2026 and 4.0% above the 52-week low of $23.82, near the bottom of the past year's range. VKTX is down 29.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 27.7%.

Viking Therapeutics has posted a net loss over the last twelve months (EPS of -$5.42), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Viking Therapeutics

Company profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Brian Lian Ph.D.
Headquarters
San Diego, CA
Employees
74
IPO year
2015

Financial highlights

Full financials

In fiscal 2025, Viking Therapeutics generated $0 in revenue, up 0.0% from fiscal 2024. Viking Therapeutics reported a net loss of $359.6 million, compared with a loss of $110.0 million a year earlier. Diluted earnings per share came in at -$3.19.

Viking Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$0$0$0$0
Growth—————
Net income$-359.64M$-109.96M$-85.89M$-68.87M$-54.99M
EPS (diluted)$-3.19$-1.01$-0.91$-0.90$-0.71

Analyst forecast

Forecast

Consensus (21 analysts)

strong_buy

Avg. price target

$95.32+284.82%

  • Strong buy 5
  • Buy 14
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $34.00High $125.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 28, 2026
EPS actual vs est.
$-0.81 vs $1.00
Surprise
-181.00%

VKTX news

All VKTX news

Viking Therapeutics peers

Health Care sector
VKTX peer companies
CompanyPrice% ChgMarket capCompare
ABCLAbCellera Biologics Inc.9.69-7.45%$3.16Bvs VKTX
XERSXeris Biopharma Holdings Inc.16.97+2.11%$3.10Bvs VKTX
BHCBausch Health Companies Inc.8.22-3.97%$3.08Bvs VKTX
ARQTArcutis Biotherapeutics Inc.26.36-2.98%$3.33Bvs VKTX
AMLXAmylyx Pharmaceuticals Inc.26.02-0.69%$3.35Bvs VKTX
LEGNLegend Biotech Corporation ADR15.25-5.28%$2.96Bvs VKTX
ACADACADIA Pharmaceuticals Inc.17.11-2.73%$2.96Bvs VKTX
VRDNViridian Therapeutics Inc.29.96-4.71%$3.40Bvs VKTX

Indexes, lists and sector

Viking Therapeutics stock FAQ

What is Viking Therapeutics's stock price today?

VKTX last traded at $24.77 as of Nov 20, 4:00 PM EST, down 4.14% on the day. Prices are delayed at least 15 minutes.

Who is Viking Therapeutics's CEO?

Dr. Brian Lian Ph.D. is the chief executive officer of Viking Therapeutics Inc., which has about 74 employees.

What is the VKTX 52-week high?

The 52-week high for VKTX is $43.10 and the 52-week low is $23.82. The stock is currently 42.5% below its high.

Compare VKTX